Skip to main content

Day: February 15, 2021

Scanfil Oyj:n tilinpäätöstiedotteen julkistaminen ja esittely verkossa

Scanfil Oyj:n tilinpäätöstiedotteen julkistaminen ja esittely verkossaSCANFIL OYJ SIJOITTAJAUUTINEN                   15.2.2021 klo 10.00SCANFIL OYJ:N TILINPÄÄTÖSTIEDOTTEEN JULKISTAMINEN JA ESITTELY VERKOSSAScanfil Oyj julkistaa 1.1.-31.12.2020 tilinpäätöstiedotteen torstaina 18.2.2021 klo 08.00. Analyytikoilla, sijoittajilla ja tiedotusvälineillä on mahdollisuus seurata tilinpäätöstiedotteen esittelyä samana päivänä 18.2.2021 klo 10.00 alkaen verkossa. Tilaisuuteen voi osallistua  https://scanfil.videosync.fi/2020-tulokset kautta.Tilinpäätöstiedotteen esittelee toimitusjohtaja Petteri Jokitalo. Analyytikot, sijoittajat ja tiedotusvälineet voivat lähettää ennakkoon tilinpäätöstiedotteeseen liittyviä kysymyksiä sähköpostiosoitteeseen minna.oksanen@scanfil.com 18.2.2021 klo 9.00 saakka. Tilaisuudessa on myös mahdollista laittaa kysymyksiä...

Continue reading

ArcelorMittal announces share buyback program

 15 February 2021, 08:00 CETArcelorMittal (‘the Company’) today announces a share buyback program (the ‘Program’) under the authorization given by the annual general meeting of shareholders held on June 13, 2020 (the ‘AGM Authorization’).For the background to this Program, reference is made to the Company’s press release dated 9 February relating to the Company selling 40 million Cleveland-Cliffs common shares for gross proceeds of US$652 million.The shares acquired under the Program are intended:1) To meet ArcelorMittal’s obligations under debt obligations exchangeable into equity securities, and/or;2) To reduce its share capital.ArcelorMittal intends to repurchase shares for an aggregate maximum amount of US$650 million in accordance with the AGM Authorization and applicable market abuse regulations. The Program will commence today1.Furthermore,...

Continue reading

UTI GROUP : CHIFFRE D’AFFAIRES ANNUEL 2020 : 18,02 M€

Communiqué de presse                                                                                                        Paris le 15 février 2021Chiffre d’affaires annuel 2020 : 18,02 M€UTI GROUP, Entreprise de Services du Numérique (ESN) dédiée au conseil et à l’intégration des nouvelles technologies au sein des grandes entreprises, publie son chiffre d’affaires annuel consolidé au 31 décembre 2020 permettant de faire ressortir les éléments comparatifs suivants :    Selon l’information sectorielle retenue dans les comptes consolidés, le chiffre d’affaires consolidé se décompose ainsi :(*) : Non AuditésA l’issue de l’exercice 2020, UTI GROUP enregistre un chiffre d’affaires consolidé de 18,02 M€, en retrait de 23,3 % par rapport au chiffre d’affaires de l’exercice 2019. Cette baisse résulte principalement du ralentissement de...

Continue reading

ArcelorMittal announces share buyback program

 15 February 2021, 08:00 CETArcelorMittal (‘the Company’) today announces a share buyback program (the ‘Program’) under the authorization given by the annual general meeting of shareholders held on June 13, 2020 (the ‘AGM Authorization’).For the background to this Program, reference is made to the Company’s press release dated 9 February relating to the Company selling 40 million Cleveland-Cliffs common shares for gross proceeds of US$652 million.The shares acquired under the Program are intended:1) To meet ArcelorMittal’s obligations under debt obligations exchangeable into equity securities, and/or;2) To reduce its share capital.ArcelorMittal intends to repurchase shares for an aggregate maximum amount of US$650 million in accordance with the AGM Authorization and applicable market abuse regulations. The Program will commence today1.Furthermore,...

Continue reading

Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients

Press releaseSynairgen plc(‘Synairgen’ or the ‘Company’)                                          Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatientsSouthampton, UK – 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled interferon beta formulation (SNG001) sub-study of the ACTIV-2 Phase II/III trial, evaluating patients with mild to moderate COVID-19 symptoms not yet requiring hospitalisation.Richard Marsden, CEO of Synairgen, said: “We are delighted that our inhaled interferon beta formulation has been entered into this US Government-funded Phase II/III study and that dosing has now commenced. With mutations of COVID-19 now emerging, and...

Continue reading

UTI GROUP : CHIFFRE D’AFFAIRES ANNUEL 2020 : 18,02 M€

Communiqué de presse                                                                                                        Paris le 15 février 2021Chiffre d’affaires annuel 2020 : 18,02 M€UTI GROUP, Entreprise de Services du Numérique (ESN) dédiée au conseil et à l’intégration des nouvelles technologies au sein des grandes entreprises, publie son chiffre d’affaires annuel consolidé au 31 décembre 2020 permettant de faire ressortir les éléments comparatifs suivants :    Selon l’information sectorielle retenue dans les comptes consolidés, le chiffre d’affaires consolidé se décompose ainsi :(*) : Non AuditésA l’issue de l’exercice 2020, UTI GROUP enregistre un chiffre d’affaires consolidé de 18,02 M€, en retrait de 23,3 % par rapport au chiffre d’affaires de l’exercice 2019. Cette baisse résulte principalement du ralentissement de...

Continue reading

Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatients

Press releaseSynairgen plc(‘Synairgen’ or the ‘Company’)                                          Synairgen announces that dosing has commenced with its inhaled interferon beta product in US Government-funded NIH ACTIV-2 trial in COVID-19 outpatientsSouthampton, UK – 15 February 2021: Synairgen plc (LSE: SNG), the respiratory drug discovery and development company, today announces that dosing has begun in the inhaled interferon beta formulation (SNG001) sub-study of the ACTIV-2 Phase II/III trial, evaluating patients with mild to moderate COVID-19 symptoms not yet requiring hospitalisation.Richard Marsden, CEO of Synairgen, said: “We are delighted that our inhaled interferon beta formulation has been entered into this US Government-funded Phase II/III study and that dosing has now commenced. With mutations of COVID-19 now emerging, and...

Continue reading

WESTPAY APPOINTS ABG SUNDAL COLLIER AS LIQUIDITY PROVIDER

Westpay AB, a leading fintech company, has entered into an agreement with ABG Sundal Collier ASA that they will act as a liquidity provider for Westpay’s share.The commitment takes place within the framework of Nasdaq Stockholm AB’s rules on liquidity enhancement and means that the liquidity provider quotas the purchase and sale volume corresponding to at least SEK 15,000 with a spread of a maximum of 4% between the buy and sell price. The purpose is to promote the share’s liquidity and the commitment will begin on February 15, 2021.For additional information, please contact:Sten Karlsson, CEO Westpay ABMobile: +46 70-555 6065Email: sten.karlsson@westpay.seLars Levin, CFO Westpay ABMobile: +46 70-8966 404Email: lars.levin@westpay.seWestpay’s Certified Adviser is Erik Penser Bank,phone: +46 8-463 80 00, email: certifiedadviser@penser.se AttachmentPressrelease_20210215_Westpay...

Continue reading

WESTPAY APPOINTS ABG SUNDAL COLLIER AS LIQUIDITY PROVIDER

Westpay AB, a leading fintech company, has entered into an agreement with ABG Sundal Collier ASA that they will act as a liquidity provider for Westpay’s share.The commitment takes place within the framework of Nasdaq Stockholm AB’s rules on liquidity enhancement and means that the liquidity provider quotas the purchase and sale volume corresponding to at least SEK 15,000 with a spread of a maximum of 4% between the buy and sell price. The purpose is to promote the share’s liquidity and the commitment will begin on February 15, 2021.For additional information, please contact:Sten Karlsson, CEO Westpay ABMobile: +46 70-555 6065Email: sten.karlsson@westpay.seLars Levin, CFO Westpay ABMobile: +46 70-8966 404Email: lars.levin@westpay.seWestpay’s Certified Adviser is Erik Penser Bank,phone: +46 8-463 80 00, email: certifiedadviser@penser.se AttachmentPressrelease_20210215_Westpay...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.